DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort.
450K DNA methylation
Epigenetically Dysregulated Signalling pathways
NPY and FAIM2hyper-methylation
Pancreatic-ductal adenocarcinoma
Poor survival
Prognostic epigenetic marker
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
03 Nov 2022
03 Nov 2022
Historique:
received:
28
03
2022
accepted:
17
09
2022
entrez:
4
11
2022
pubmed:
5
11
2022
medline:
5
11
2022
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading cancers worldwide and has a poor survival, with a 5-year survival rate of only 8.5%. In this study we investigated altered DNA methylation associated with PDAC severity and prognosis. Methylome data, generated using 450 K bead array, was compared between paired PDAC and normal samples in the TCGA cohort (n = 9) and our Indian cohort (n = 7). The total Indian Cohort (n = 75) was split into cohort 1 (n = 7), cohort 2 (n = 22), cohort 3 (n = 26) and cohort 4 (n = 20).Validation of differential methylation (6 selected CpG loci) and associated gene expression for differentially methylated genes (10 selected gDMs) were carried out in separate validation cohorts, using MSP, RT-PCR and IHC correlations between methylation and gene expression were observed in TCGA, GTEx cohorts and in validation cohorts. Kaplan-Meier survival analysis was done to study differential prognosis, during 2-5 years of follow-up. We identified 156 DMPs, mapped to 91 genes (gDMs), in PDAC; 68 (43.5%) DMPs were found to be differentially methylated both in TCGA cohort and our cohort, with significant concordance at hypo- and hyper-methylated loci. Enrichments of "regulation of ion transport", "Interferon alpha/beta signalling", "morphogenesis and development" and "transcriptional dysregulation" pathways were observed among 91 gDMs. Hyper-methylation of NPY and FAIM2 genes with down-regulated expression in PDAC, were significantly associated with poor prognosis in the Indian patient cohort. Ethnic variations among populations may determine the altered epigenetic landscape in the PDAC patients of the Indian cohort. Our study identified novel differentially methylated genes (mainly NPY and FAIM2) and also validated the previously identified differentially methylated CpG sites associated with PDAC cancer patient's survival. Comparative analysis of our data with TCGA and CPTAC cohorts showed that both NPY and FAIM2 hyper-methylation and down-regulations can be novel epigenetically regulated genes in the Indian patient population, statistically significantly associated with poor survival and advanced tumour stages.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading cancers worldwide and has a poor survival, with a 5-year survival rate of only 8.5%. In this study we investigated altered DNA methylation associated with PDAC severity and prognosis.
METHODS
METHODS
Methylome data, generated using 450 K bead array, was compared between paired PDAC and normal samples in the TCGA cohort (n = 9) and our Indian cohort (n = 7). The total Indian Cohort (n = 75) was split into cohort 1 (n = 7), cohort 2 (n = 22), cohort 3 (n = 26) and cohort 4 (n = 20).Validation of differential methylation (6 selected CpG loci) and associated gene expression for differentially methylated genes (10 selected gDMs) were carried out in separate validation cohorts, using MSP, RT-PCR and IHC correlations between methylation and gene expression were observed in TCGA, GTEx cohorts and in validation cohorts. Kaplan-Meier survival analysis was done to study differential prognosis, during 2-5 years of follow-up.
RESULTS
RESULTS
We identified 156 DMPs, mapped to 91 genes (gDMs), in PDAC; 68 (43.5%) DMPs were found to be differentially methylated both in TCGA cohort and our cohort, with significant concordance at hypo- and hyper-methylated loci. Enrichments of "regulation of ion transport", "Interferon alpha/beta signalling", "morphogenesis and development" and "transcriptional dysregulation" pathways were observed among 91 gDMs. Hyper-methylation of NPY and FAIM2 genes with down-regulated expression in PDAC, were significantly associated with poor prognosis in the Indian patient cohort.
CONCLUSIONS
CONCLUSIONS
Ethnic variations among populations may determine the altered epigenetic landscape in the PDAC patients of the Indian cohort. Our study identified novel differentially methylated genes (mainly NPY and FAIM2) and also validated the previously identified differentially methylated CpG sites associated with PDAC cancer patient's survival. Comparative analysis of our data with TCGA and CPTAC cohorts showed that both NPY and FAIM2 hyper-methylation and down-regulations can be novel epigenetically regulated genes in the Indian patient population, statistically significantly associated with poor survival and advanced tumour stages.
Identifiants
pubmed: 36329447
doi: 10.1186/s12935-022-02737-1
pii: 10.1186/s12935-022-02737-1
pmc: PMC9635159
doi:
Types de publication
Journal Article
Langues
eng
Pagination
334Subventions
Organisme : Department of Biotechnology, Ministry of Science and Technology, India
ID : RLS/BT/Re-Entry/05/2012
Informations de copyright
© 2022. The Author(s).
Références
Cell. 2012 Jul 6;150(1):12-27
pubmed: 22770212
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Epigenetics Chromatin. 2019 Dec 5;12(1):71
pubmed: 31805986
Cancers (Basel). 2020 Jun 30;12(7):
pubmed: 32629766
Clin Epigenetics. 2019 Sep 6;11(1):132
pubmed: 31492175
Int J Biol Sci. 2020 Feb 10;16(7):1153-1165
pubmed: 32174791
BMC Cancer. 2021 Oct 10;21(1):1092
pubmed: 34627187
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Gastroenterology. 2020 Jun;158(8):2072-2081
pubmed: 32199881
Am J Physiol Cell Physiol. 2011 May;300(5):C1078-89
pubmed: 21270292
Mol Genet Genomics. 2017 Feb;292(1):5-35
pubmed: 27815639
Curr Genomics. 2018 Sep;19(6):444-463
pubmed: 30258276
Epigenomes. 2021 Apr 09;5(2):
pubmed: 34968295
BMC Genomics. 2014 Mar 26;15:119
pubmed: 24669864
Eur Urol Oncol. 2019 Jul;2(4):405-412
pubmed: 31164324
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Mol Med. 2020 Jun 17;26(1):59
pubmed: 32552660
Pharmacol Ther. 2011 Jul;131(1):91-113
pubmed: 21439311
Clin Cancer Res. 2011 Jul 1;17(13):4341-54
pubmed: 21610144
Clin Epigenetics. 2015 Jul 25;7:75
pubmed: 26213588
Pancreas. 2017 May/Jun;46(5):614-618
pubmed: 28196014
Epigenomics. 2016 Jun;8(6):831-42
pubmed: 27337224
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2647-56
pubmed: 25450338
Semin Cancer Biol. 2018 Aug;51:149-159
pubmed: 28807546
FASEB J. 2020 Jan;34(1):161-179
pubmed: 31914609
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Anticancer Res. 2020 Aug;40(8):4445-4455
pubmed: 32727774
Cancers (Basel). 2019 Oct 25;11(11):
pubmed: 31731482
Front Oncol. 2021 Sep 09;11:690142
pubmed: 34568020
Regen Biomater. 2015 Sep;2(3):215-9
pubmed: 26816643
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
World J Gastroenterol. 2019 Oct 14;25(38):5732-5772
pubmed: 31636470
Clin Epigenetics. 2022 Feb 22;14(1):28
pubmed: 35193708
Genome Biol. 2015 May 21;16:103
pubmed: 25990550
Hepatobiliary Pancreat Dis Int. 2020 Jun;19(3):205-217
pubmed: 32312637
Genes Dis. 2018 Feb 21;5(1):43-45
pubmed: 30258934
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8771-6
pubmed: 27439875
J Cell Biochem. 2019 Nov;120(11):18762-18770
pubmed: 31265172
Cell Physiol Biochem. 2019;53(S1):44-51
pubmed: 31834994
J Neurochem. 2016 Oct;139(1):11-21
pubmed: 27385439
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1452-1462.e4
pubmed: 27266982
Nat Commun. 2019 Aug 28;10(1):3875
pubmed: 31462645
Int J Cancer. 2014 Sep 1;135(5):1110-8
pubmed: 24500968
Diab Vasc Dis Res. 2015 May;12(3):217-20
pubmed: 25696115
Sci Rep. 2016 Sep 28;6:34022
pubmed: 27677402
Future Oncol. 2016 Aug;12(16):1929-46
pubmed: 27246628
Sci Rep. 2014 Feb 26;4:4197
pubmed: 24569397
Nature. 2012 Nov 15;491(7424):399-405
pubmed: 23103869
PLoS One. 2018 Aug 27;13(8):e0202856
pubmed: 30148861
Oncotarget. 2017 Apr 25;8(17):28990-29012
pubmed: 28423671
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Nat Genet. 2011 Jun 26;43(8):768-75
pubmed: 21706001